Pluristem Life Systems, Inc. Retains Strategic Growth as a Global Investor Relations Advisor

Wednesday April 18, 8:00 am ET

Founded in 1989, SGI is headed by Stanley Altschuler and Richard Cooper, two long-time and highly respected Wall Street veterans, who have assembled an experienced team of investment/financial professionals including specialists in life science companies and with international growth companies such as Pluristem. Since its inception in 1989, Strategic Growth has achieved an unparalleled success for over 150 clients.

Mr. Zami Aberman, President and Chief Executive Officer of Pluristem Life Systems, stated, "Pluristem has made substantial progress in creating a dynamic business platform and in achieving important strategic steps that will position the Company for continued growth." We are pleased to add a firm like Strategic Growth to our team. Together we will actively meet with investors in the coming months to ensure that our progress is known by the investment community."

Richard Cooper, Chairman of Strategic Growth, added that "Global investors in the emerging company space have developed a growing awareness of the exciting potential that companies have in the stem cell therapy space, particularly those like Pluristem that have made significant progress in commercializing their proprietary technology. We made a careful decision to utilize our close contact with institutional investors and our resource base to bring the Pluristem story to the investment community."

ABOUT PLURISTEM:

Pluristem Life Systems, Inc., is a biotechnology Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-BMT, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).

Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.

Additional information about Pluristem can be found on the Web at www.pluristem.com.

SAFE HARBOR STATEMENT:

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release, include that PLX-BMT, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT); that the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation; that Company future products will participate in the approximate $30 billion therapeutic and regenerative cellular market; that we will have continued growth. Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.


For more information visit our website at www.pluristem.com